Development of Tools (and prediction rules) to time and select therapy in treatment of pre-clinical, early and established Rheumatoid Arthritis: Creating Enhanced Remedy (TRACER): established reumatoid arthritis

Development of Tools (and prediction rules) to time and select therapy in treatment of pre-clinical, early and established Rheumatoid Arthritis: Creating Enhanced Remedy (TRACER): established reumatoid arthritis - TRACER/ESRA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39156

Enrollment

300

Registered

2013-06-10

Start date

2014-02-06

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with established rheumatoid arthritis who are starting treatment with a biological (anti-TNFa, anti-IL-6, B cel inhibition or anti-costimulatory therapie)

Exclusion criteria

Exclusion criteria: -patients with another rheumatological disease, that requires treatment with a biological

Design outcomes

Primary

Measure	Time frame
Response to treatment with biologics in patients with RA, based on EULAR and ACR response criteria. Prediction of response via in vitro assays 1) ACPA profiling 2) cytokine, chemokine and adipokine profiling 3) (epi) genetic profiling	—

Secondary

Measure	Time frame
Cost effectiveness of (combinations of) in vitro tests in predicting response to biological treatment compared to existing tests such as RF and aCCP	—

Countries

Netherlands

Outcome results